Innovative production of highly potent equine neutralizing antibody against Hemiscorpius lepturus scorpion venom using recombinant mPLD1 protein.

Overview

• This research focuses on creating a highly potent antivenom against Hemiscorpius lepturus scorpion venom using a recombinant non-toxic mutant phospholipase D protein (mPLD1) to immunize horses, resulting in antibodies that are significantly more effective than existing commercial antisera.

Background and Importance

• Hemiscorpius lepturus is a dangerous scorpion species, whose venom causes severe health issues and even death.
• The main toxic agent in this venom is a phospholipase D (PLD) enzyme, which disrupts biological systems and leads to systemic complications.
• Previous studies identified a native PLD toxin as critical for the venom’s lethality.

Development of Recombinant Proteins

• A recombinant version of the toxic PLD protein, called PLD1, was developed and shown to retain its toxic properties.
• A mutant form of this recombinant PLD1, termed mPLD1, was engineered to be non-toxic and safe by removing its lethal effects.
• These recombinant proteins were central to the production of innovative, targeted antivenoms.

Immunization and Antibody Production

• Two horses were immunized separately: one with recombinant toxic PLD1 and the other with non-toxic mPLD1.
• Both immunogens triggered the production of high-titer antisera, with no significant difference in the antibody levels between the two groups.
• The antibodies were purified to yield F(ab’)2 fragments, which are effective for neutralizing toxins.

Comparison with Commercial Antisera

• The purified F(ab’)2 antibodies from the horses showed significantly higher specificity in recognizing PLD1 and crude venom compared to commercial antivenoms.
• In vivo neutralization tests demonstrated that antisera derived from mPLD1-immunized horses was:
• 89 times more potent than one commercial antiserum
• 36 times more potent than another commercial antiserum
• The findings indicate that antibodies targeting the recombinant mPLD1 protein have superior neutralizing capability against H. lepturus venom toxins.

Implications for Antivenom Production

• The recombinant mPLD1 protein offers a non-toxic, safe, and straightforward immunogen for antivenom production.
• Production methods for this recombinant protein are cost-effective, facilitating scalable manufacturing.
• Using this approach can substantially improve the efficacy and safety of horse-derived antisera against scorpion venom.
• The research suggests that focusing on recombinant mPLD1-based antivenoms could revolutionize treatment for H. lepturus envenomation and potentially other venomous scorpions with similar toxins.

Summary

• This study successfully produced potent equine neutralizing antibodies using a recombinant, non-toxic phospholipase D mutant from H. lepturus venom.
• The resulting antivenom is far more specific and effective than current commercial alternatives.
• The findings pave the way for improved, economical antivenom production strategies, potentially reducing morbidity and mortality from scorpion stings.